Alex Philippidis is a Senior Business Editor at Inside Precision Medicine and Genetic Engineering & Biotechnology News. He focuses on themes such as medicine and healthcare, alternative medicine, and finance, with particular attention to topics like AI, startups, and venture capital. Alex's work has been featured in prominent publications, showcasing his expertise in the intersection of science and business.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Alex Philippidis mainly covers healthcare and pharmaceutical industry, focusing on investment analysis, private sector announcements, and press releases. He would likely be interested in receiving pitches related to breakthroughs in drug development, acquisitions within the biopharmaceutical industry, advancements in gene therapy as well as the application of AI in healthcare.
Given his interest in citing data and investment analysis, he might appreciate pitches that provide substantial data-driven insights into trends or companies within the healthcare and pharmaceutical sectors. Additionally, pitches featuring exclusive access to company executives for interviews or providing unique perspectives on M&A activities could also resonate with him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Alex Philippidis
Q32 Bio faced a sharp market reaction as shares plunged 85% following mixed mid-stage trial results for its lead candidate, bempikibart, in alopecia areata and atopic dermatitis. The stock closed just $0.03 above its 52-week low.
By: Alex Philippidis
NVentures invests further in Stanford spinout to accelerate development of platform designed to optimize molecules for complex targets in oncology, immunology
By: Alex Philippidis
GEN presents data compiled by Morningstar's Morningstar Direct asset management platform for StockWatch of the top five performing biotech stocks of 2024, and the five biotech stocks that fell the most during this past year, with brief explanations for the increases or declines.
By: Alex Philippidis
After years of regulatory and financial challenges, C-suite executives anticipate a (mostly) happy new year with a comeback for VC funding, M&A, and IPOs
By: Alex Philippidis
Market capitalization of the largest public biotech companies jumps nearly 12% year-over-year, as all but five of them show gains.
By: Alex Philippidis
Novo Nordisk and Valo Health have expanded their 16-month-old collaboration into an up-to-$4.6 billion-plus artificial intelligence (AI) partnership aimed at discovering and developing up to 20 treatments for obesity, type 2 diabetes, and cardiovascular disease.
By: Alex Philippidis
Investors sell off AMD shares despite the company's pivot to life sciences AI, following a rating downgrade by HSBC that followed a six-month decline in the stock price.
By: Alex Philippidis
EY—the professional services firm originally known as Ernst & Young—reports the dollar value of biopharma M&A deals nosedived 51% during 2024, to 92 from 186 the previous year.
By: Alex Philippidis
Credit: John Lund / Getty Images Johnson & Johnson has agreed to acquire Intra-Cellular Therapies for approximately $14.6 billion, the
By: Alex Philippidis
Illumina will offer its DRAGEN analysis software on Nvidia's accelerated computing platforms through the next-gen sequencing giant's Illumina Connected Analytics (ICA) platform. By integrating their technologies, the companies aim to expand the reach of DRAGEN and Illumina multi-omics analysis globally to wherever users access Nvidia's computing platform.
(833) 317-6278 
